Plain-English translation of NCT02901184 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a medication that helps manage blood pressure and fluid in the body, can help people with a specific type of heart failure called heart failure with preserved ejection fraction (HFPEF). In this condition, the heart pumps normally but doesn't relax well, causing fluid buildup and breathing problems. The study will compare patients who take this medication along with their usual care to those who receive usual care alone, measuring whether the treatment reduces deaths and hospital stays.
Heart failure with preserved ejection fraction is common and serious, but doctors don't have proven treatments for it yet. Earlier studies hinted that this medication might help, but more research is needed to confirm whether it actually works and is safe for these patients.
You likely qualify if…
You likely don't qualify if…
If enrolled, you'll be randomly assigned to either take the medication (starting at 25 mg daily, increasing to 50 mg if tolerated) on top of your regular heart failure care, or to continue with standard care alone. The study lasts about 9 years, with your outcomes tracked through medical records, hospital data, and periodic contact — in Sweden this happens automatically through health registries, while in the US your clinic and a call center will check on your progress. Your role is to take the medication as prescribed, attend follow-up visits, and allow researchers to monitor whether you're hospitalized or have other health events.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States